Tikun Olam-Cannbit Pharmaceuticals Ltd

Tel Aviv Stock Exchange TKUN.TA

Tikun Olam-Cannbit Pharmaceuticals Ltd Net Income Margin for the year ending December 31, 2023: -200.97%

Tikun Olam-Cannbit Pharmaceuticals Ltd Net Income Margin is -200.97% for the year ending December 31, 2023, a -105.40% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.
  • Tikun Olam-Cannbit Pharmaceuticals Ltd Net Income Margin for the year ending December 31, 2022 was -97.85%, a -10.97% change year over year.
  • Tikun Olam-Cannbit Pharmaceuticals Ltd Net Income Margin for the year ending December 31, 2021 was -88.17%, a 42.02% change year over year.
  • Tikun Olam-Cannbit Pharmaceuticals Ltd Net Income Margin for the year ending December 31, 2020 was -152.09%.
Key data
Date Net Income Margin EBITDA Margin EBIT Margin EBITDA
Market news
SV Wall Street
Tel Aviv Stock Exchange: TKUN.TA

Tikun Olam-Cannbit Pharmaceuticals Ltd

CEO Mr. Ronen Elad
IPO Date Aug. 12, 2002
Location Israel
Headquarters Hitad 2
Employees 50
Sector Healthcare
Industries
Pharmaceuticals Biotechnology Clinical Trials Tobacco Vaccines
Description

Tikun Olam-Cannbit Pharmaceuticals Ltd engages in the research, development, cultivation, manufacture, and distribution of medical cannabis and related products. It also provides training and patient care services. The company is based in Nof Hagalil, Israel.

StockViz Staff

February 6, 2025

Any question? Send us an email